oilinwat
emuls
adjuv
approv
influenza
vaccin
human
use
europ
due
induc
properti
seldom
test
cancer
vaccin
studi
formul
ctype
cpg
oligodeoxynucleotid
test
adjuv
activ
induc
immun
respons
recombin
fusion
protein
incorpor
mycobacteri
heat
shock
protein
mucin
cell
surfac
associ
deriv
peptid
combin
could
confer
potent
bias
properti
adjuv
enhanc
immunogen
induc
significantli
higher
level
specif
increas
mrna
express
splenocyt
gener
antigenspecif
cytotox
lymphocyt
mice
prophylact
appli
adjuv
contain
inhibit
growth
melanoma
prolong
surviv
tumorbear
mice
contrast
adjuv
contain
absenc
promot
growth
melanoma
mice
result
suggest
plu
cpg
oligodeoxynucleotid
might
develop
effici
adjuv
tumor
vaccin
melanoma
possibl
tumor
ideal
potent
cancer
vaccin
induc
strong
helper
th
cell
mediat
immun
respons
gener
antigenspecif
cytotox
lymphocyt
ctl
howev
self
molecul
tumor
antigen
cancer
vaccin
poorli
immunogen
therefor
requir
use
adjuv
enhanc
abil
elicit
strong
cellular
immun
respons
gener
adjuv
serv
enhanc
magnitud
breadth
qualiti
longev
specif
immun
respons
antigen
compos
vehicl
immunestimul
vehicl
miner
salt
emuls
liposom
function
control
releas
deliveri
antigen
last
decad
pathogenassoci
molecular
pattern
pamp
identifi
innat
immun
stimul
capabl
activ
antigen
present
cell
especi
dendrit
cell
dc
process
present
antigen
produc
cytokin
chemokin
upregul
costimulatori
molecul
effici
allow
combin
pamp
mimic
vehicl
compound
emuls
develop
effici
adjuv
oilinwat
nanoemuls
licens
europ
use
elderli
adjuv
season
influenza
vaccin
current
evalu
pandem
vaccin
prepar
ww
squalen
oil
phase
squalen
biodegrad
oil
extract
shark
liver
occur
higher
organ
includ
human
intermedi
cholesterol
vitamin
synthesi
pathway
addit
emuls
properti
enhanc
antigen
uptak
activ
dc
facilit
immun
respons
antigen
current
evalu
preclin
studi
clinic
trial
adjuv
microbi
antigen
hepat
b
viru
hbv
hepat
c
viru
hcv
cytomegaloviru
cmv
human
papillomaviru
hpv
sar
coronaviru
serogroup
b
meningococcu
human
immunodefici
virus
hiv
herp
simplex
viru
studi
use
facilit
bias
antibodi
respons
microbi
antigen
confer
immun
responsepromot
properti
pamp
mimic
toll
like
receptor
tlr
ligand
ad
mice
combin
chemic
synthes
agonist
induc
mix
immun
respons
hemagglutinin
ha
influenza
viru
compos
produc
cell
immunoglobulin
ig
antibodi
combin
agonist
cpg
contain
oligodeoxynucleotid
cpg
odn
immun
mice
potent
cellular
immun
respons
repres
intern
immunopharmacolog
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
n
p
higher
titer
induct
strongli
enhanc
respons
observ
splenocyt
recent
cpg
odn
investig
adjuv
tumor
vaccin
due
abil
induc
enhanc
innat
adapt
immun
respons
consequ
evalu
clinic
trial
base
function
characterist
cpg
odn
divid
b
c
subtyp
atyp
cpg
odn
induc
plasmacytoid
dendrit
cell
pdc
secret
larg
amount
btype
cpg
odn
stimul
prolifer
antibodi
product
b
cell
ctype
cpg
odn
share
properti
atyp
btype
cpg
odn
clinic
trial
cpg
odn
especi
btype
cpg
odn
evalu
efficaci
adjuv
cancer
vaccin
melanoma
patient
cpg
btype
cpg
odn
formul
incomplet
freund
adjuv
melanoma
antigen
induc
vigor
cellular
immun
respons
gener
high
number
melanomaspecif
cytotox
lymphocyt
ctl
cpg
mix
synthet
peptid
incomplet
freund
adjuv
led
earli
induct
specif
integr
th
cell
develop
antigenspecif
immun
respons
nine
patient
express
tumor
six
nine
patient
surviv
averag
month
significantli
longer
predict
surviv
month
addit
vaccin
peptid
epitop
deriv
novel
cancertesti
antigen
combin
cpg
success
elicit
antigenspecif
cell
respons
enhanc
innat
immun
patient
advanc
esophag
squamou
cell
carcinoma
current
studi
investig
use
pamp
mimic
confer
bias
capabl
effici
adjuv
tumor
antigen
use
formul
ctype
cpg
odn
enhanc
immunogen
recombin
fusion
protein
mycobacteri
heat
shock
protein
human
vntr
peptid
prophylact
appli
induct
vigor
cellular
immun
respons
inhibit
growth
melanoma
mice
prolong
surviv
rate
thu
combin
pamp
mimic
may
use
vaccin
tumor
antigen
clinic
femal
mice
week
purchas
beij
weitonglihua
laboratori
anim
co
ltd
mice
maintain
microisol
cage
pathogenfre
condit
anim
care
conform
guid
care
use
laboratori
anim
nation
research
council
murin
melanoma
cell
origin
transfect
vntr
plasmid
encod
human
vntr
peptid
fuse
gfp
cell
line
select
complet
medium
contain
mgl
sigmaaldrich
st
loui
mo
cell
clone
stabl
monoclon
transfect
cell
verifi
fluoresc
microscopi
complet
medium
prepar
supplement
fetal
bovin
serum
fb
vv
antibiot
iuml
penicillin
iuml
streptomycin
cell
line
cultur
co
humidifi
incub
mw
kda
construct
lab
contain
bcg
two
copi
vntr
core
peptid
gstappahgvtsapdtrpapgstappahgvtsapdnrp
express
e
coli
purifi
previous
describ
recombin
protein
verifi
western
blot
analysi
use
monoclon
antibodi
mab
prepar
lab
mous
antihuman
mab
bd
bioscienc
fl
nj
squalen
prepar
nm
sodium
citrat
buffer
describ
nucleaseresist
phosphorothioatemodifi
odn
synthes
takara
co
dalian
china
cpg
odn
use
studi
c
type
lowercas
letter
repres
phosphorothio
linkag
cpg
odn
dilut
pb
test
endotoxin
use
limulu
amebocyt
lysat
assay
associ
cape
cod
inc
east
falmouth
reagent
use
pyrogenfre
vaccin
prepar
mix
andor
cpg
odn
vv
ratio
solubl
andor
cpg
odn
ad
emuls
prior
immun
tumorsuppress
experi
carri
mice
use
follow
two
protocol
either
prophylact
therapeut
vaccin
prophylact
protocol
mice
immun
alon
combin
odn
cpg
odn
alon
subcutan
sc
inguin
lymph
node
area
day
therapeut
protocol
mice
immun
day
tumor
cell
inocul
mous
inject
sc
cell
back
near
hind
leg
day
tumor
size
measur
everi
two
day
calip
tumor
greater
mm
diamet
progress
growth
record
posit
surviv
mice
monitor
approxim
day
immunogen
studi
mice
immun
alon
mix
odn
sc
inguin
lymph
node
area
per
mous
two
four
time
interv
sacrif
mice
sera
collect
antibodi
analysi
splenocyt
isol
detect
mrna
express
cell
activ
day
fourth
immun
splenocyt
prepar
isol
total
rna
use
trizol
reagent
invitrogen
carlsbad
ca
concentr
content
rna
analyz
use
unic
ultraviolet
spectrophotomet
ratio
indic
rna
sampl
highli
purifi
degrad
revers
transcript
reaction
carri
use
tianscript
mmlv
tiangen
biotech
beij
china
accord
manufactur
instruct
mrna
quantifi
realtim
pcr
use
abi
prism
fast
realtim
pcr
system
primer
synthes
sangon
biotech
shanghai
china
realtim
pcr
reaction
perform
total
volum
use
premix
ex
ii
quantit
augment
reaction
system
takara
dalian
china
level
mrna
splenocyt
calcul
normal
cycl
threshold
housekeep
gene
gapdh
present
fold
chang
valu
threshold
rel
control
splenocyt
mice
serum
mice
detect
day
fourth
immun
elisa
plate
coat
overnight
pb
mmoll
kh
po
mmoll
na
hpo
mmoll
nacl
mmoll
kcl
ph
wash
three
time
wash
buffer
pbst
moll
pb
block
buffer
ad
pb
skim
milk
follow
incub
h
sera
dilut
sampl
buffer
pb
bsa
ad
well
duplic
incub
h
afterward
plate
wash
follow
addit
per
well
goat
antimous
sigma
chemic
co
st
loui
mo
dilut
incub
h
wash
substrat
solut
ophenylenediamin
dihydrochlorid
opd
amresco
solon
oh
ad
incub
room
temperatur
min
dark
color
develop
stop
moll
sulfur
acid
per
well
optic
densiti
od
valu
measur
nm
autom
elisa
plate
reader
result
express
averag
od
valu
deviat
sd
mous
splenocyt
cytotox
assay
mice
inject
sc
pb
side
inguin
lymph
node
area
day
day
splenocyt
mice
group
prepar
cultur
day
humidifi
atmospher
co
day
mous
ad
cultur
recal
splenocyt
collect
effector
cell
cocultur
melanoma
cell
target
cell
per
well
plate
effectortarget
e
ratio
h
aspir
supernat
contain
suspend
splenocyt
remain
adher
cell
collect
stain
trypan
blue
count
light
microscop
doubleblind
method
count
repeat
time
microscop
live
melanoma
cell
unstain
distinguish
residu
splenocyt
distinct
larger
size
cytotox
splenocyt
calcul
formula
cytotox
cell
number
experi
groupsviabl
cell
number
medium
control
viabl
cell
number
total
number
live
melanoma
cell
four
big
live
cell
number
four
big
squar
concentr
cell
higher
ml
mous
splenocyt
immun
mice
prepar
cultur
h
stain
fitclabel
mab
pelabel
mab
analyz
lymphocyt
activ
briefli
splenocyt
stain
fluoresc
conjug
monoclon
antibodi
min
ice
dark
wash
fac
buffer
pb
contain
mmoll
edta
mll
fb
analyz
flow
cytometri
tumor
growth
curv
plot
base
tumor
size
first
mous
die
oneway
analysi
varianc
anova
use
analyz
experiment
data
twosid
student
ttest
adopt
compar
mean
valu
individu
treatment
primari
outcom
statist
signific
surviv
estim
kaplanmei
method
evalu
logrank
test
p
valu
consid
statist
signific
statist
analys
perform
spss
softwar
assess
whether
plu
cpg
odn
odn
could
potent
adjuv
cancer
vaccin
select
recombin
fusion
protein
antigen
tumor
vaccin
melanoma
cell
melanoma
establish
transfect
fusion
gene
encod
green
fluoresc
protein
gfp
vntr
peptid
murin
melanoma
cell
target
tumor
cell
prepar
identif
sdspage
fig
western
blot
fig
alon
combin
ctype
cpg
odn
term
subcutan
sc
immun
mice
n
side
inguin
lymph
node
area
four
time
day
interv
fig
day
last
immun
melanoma
cell
per
mous
inocul
mice
fig
tumor
volum
mice
measur
everi
day
surviv
mice
calcul
result
show
could
significantli
boost
immunogen
induc
melanoma
immun
p
compar
pb
group
vaccin
alon
display
limit
role
inhibit
tumor
growth
use
either
alon
adjuv
fail
inhibit
tumor
growth
surprisingli
use
sole
adjuv
promot
signific
growth
melanoma
p
fig
importantli
mice
vaccin
significantli
prolong
surviv
rate
day
posttumor
challeng
vaccin
mice
aliv
contrast
mice
surviv
pb
alon
group
respect
group
vaccin
mice
die
earli
stage
fig
consist
fast
tumor
growth
tumor
incid
highest
group
compar
pb
alon
group
tumor
incid
respect
comparison
vaccin
significantli
decreas
tumor
incid
fig
taken
togeth
odn
may
promis
adjuv
promot
immunogen
prophylact
inhibit
tumor
next
test
whether
vaccin
could
induc
therapeut
effect
melanoma
mice
inocul
melanoma
cell
per
mous
follow
immun
alon
four
time
first
immun
perform
day
posttumor
challeng
follow
three
immun
day
interv
fig
tumor
volum
mice
measur
everi
day
surviv
mice
calcul
immun
fail
enhanc
immunogen
induc
tumor
inhibit
therapeut
model
fig
surviv
rate
mice
immun
compar
mice
immun
alon
fig
indic
odn
may
suitabl
adjuv
therapeut
applic
induc
antitumor
immun
explor
odn
could
enhanc
antitumor
effect
mice
measur
sera
mice
immun
antibodi
mice
immun
develop
high
level
serum
antibodi
compar
group
without
adjuv
howev
serum
level
significantli
higher
mice
immun
compar
alon
fig
ratio
higher
mice
immun
wherea
induc
respons
lower
ratio
observ
compar
initi
alon
fig
next
spleen
mice
isol
day
last
immun
alon
express
mrna
splenocyt
detect
use
realtim
rtpcr
immun
produc
high
level
mrna
compar
alon
group
fig
compar
induc
higher
level
mrna
alon
p
b
tend
inhibit
upregul
induc
although
statist
insignific
fig
result
impli
could
confer
properti
induc
immun
respons
mice
subsequ
spleen
mice
immun
isol
day
last
immun
splenocyt
puls
h
stain
fitclabel
mab
pelabel
mab
analyz
cell
activ
use
adjuv
strongli
induc
prolifer
cell
indic
presenc
doubl
posit
cell
fig
ratio
cell
splenocyt
mice
immun
significantli
higher
compar
mice
inject
pb
p
fig
result
suggest
odn
adjuv
may
contribut
product
tumorspecif
immun
respons
investig
whether
odn
enhanc
immunogen
induc
tumorspecif
immun
respons
splenocyt
immun
mice
cultur
day
use
effector
cell
ctl
kill
assay
shown
fig
splenocyt
mice
immun
lyse
melanoma
cell
test
differ
effector
target
e
ratio
highest
cytotox
observ
e
ratio
splenocyt
mice
immun
alon
could
also
lyse
target
cell
compar
pb
control
group
although
lower
cytotox
group
data
indic
odn
may
promis
adjuv
develop
tumor
vaccin
odn
enhanc
immunogen
induc
immunolog
memori
inhibit
tumor
investig
whether
formul
cpg
could
promot
gener
immun
memori
melanoma
five
mice
immun
challeng
melanoma
cell
rechalleng
melanoma
cell
per
mous
day
first
challeng
mice
n
inocul
melanoma
cell
use
control
surviv
mice
calcul
four
mice
succumb
melanoma
day
wherea
one
mous
die
rechalleng
group
averag
surviv
significantli
longer
rechalleng
mice
mice
p
fig
data
suggest
odn
could
assist
gener
melanomaspecif
immunolog
memori
mice
studi
demonstr
adjuv
contain
plu
cpg
odn
odn
could
prophylact
induc
tumor
immun
respons
inhibit
melanoma
growth
prolong
surviv
tumor
bear
mice
compar
adjuv
contain
alon
fail
induc
protect
immun
respons
mice
transplant
melanoma
cell
report
use
adjuv
microbi
antigen
inactiv
influenza
viru
herp
simplex
viru
induc
neutral
antibodi
virus
elev
serum
cytokin
level
includ
interleukin
il
inabl
induc
effici
immun
tumor
could
attribut
immun
responsebias
properti
consist
show
induc
significantli
elev
level
result
lower
ratio
shown
induc
cell
secret
cytokin
induc
isotyp
switch
b
cell
produc
antibodi
clinic
trial
facilit
subunit
vaccin
induc
high
titer
neutral
antibodi
specif
cell
effectormemori
phenotyp
howev
consid
suitabl
adjuv
tumor
antigen
induc
protect
cellular
immun
respons
tumor
cell
furthermor
unsuit
protect
immun
respons
cancer
demonstr
data
studi
immun
promot
growth
melanoma
phenomenon
may
aris
tumor
growth
promot
caus
immun
respons
antibodi
mediat
tumor
invas
hypothet
strong
respons
often
associ
lack
cellmedi
immun
vivo
studi
show
could
inhibit
cellmedi
immun
synergist
thu
presenc
cytokin
would
unfavor
benefici
tumor
respons
inde
lewi
lung
carcinoma
cell
grew
aggress
transgen
mice
ineffici
apc
capac
induc
mhc
alloreact
impair
ctl
respons
observ
addit
endogen
could
upregul
antiapoptot
gene
express
fibrosarcoma
cell
therefor
reduc
apoptosi
tumor
cell
thu
cytokin
milieu
tumor
antigeninduc
specif
antibodi
could
promot
tumor
growth
may
support
observ
promot
melanoma
growth
possibl
due
specif
antibodi
induc
set
creat
may
partli
confirm
evid
antisera
purifi
igg
deriv
recombin
tumor
antigen
express
melanoma
cell
immun
mice
promot
prolifer
murin
melanoma
cell
vitro
antibodi
could
caus
acceler
melanoma
growth
mice
addit
format
antibodi
tumor
antigen
complex
may
induc
granulocyt
macrophagemedi
tumor
invas
metastasi
promot
extracellular
matrix
degrad
angiogenesi
current
btype
cpg
odn
commonli
use
adjuv
tumor
antigen
preclin
studi
clinic
trial
present
studi
ctype
cpg
odn
formul
could
enhanc
immun
respons
mice
although
mechan
involv
unclear
howev
immunolog
memori
induc
immun
mice
mice
n
group
receiv
prophylact
immun
follow
transfer
melanoma
cell
rechalleng
subcutan
sc
melanoma
cell
mice
n
inocul
sc
melanoma
cell
control
surviv
mice
record
rechalleng
p
b
compar
mice
combin
might
aid
crosspresent
exogen
b
cell
gener
ctl
report
upon
cpg
odn
stimul
b
cell
could
acquir
abil
present
solubl
antigen
mhc
class
pathway
gener
cell
shown
present
studi
combin
induc
specif
cytotox
lymphocyt
second
combin
may
induc
immun
respons
melanoma
induc
high
level
pdc
addit
cpg
odn
induc
could
stimul
dc
produc
cell
produc
consequ
promot
differenti
cell
similarli
data
demonstr
induc
high
level
antigenspecif
mice
upregul
express
mrna
murin
splenocyt
vitro
notic
requir
induc
adjuv
activ
combin
alon
insuffici
inhibit
melanoma
growth
mice
may
explain
promot
dc
matur
antigen
uptak
enhanc
dc
migrat
lymph
node
provid
potent
synergi
induc
cellmedi
immun
respons
effect
overal
ctype
cpg
odn
might
suitabl
work
induc
immun
respons
assumpt
could
support
unpublish
data
formul
facilit
induc
higher
level
specif
mrna
mice
atyp
cpg
odn
btype
cpg
odn
taken
togeth
studi
demonstr
formul
ctype
cpg
odn
could
enhanc
immunogen
induc
immun
respons
specif
melanoma
immun
prophylact
formul
could
appli
prepar
tumor
antigenbas
vaccin
cancer
patient
particularli
postop
cancer
patient
use
prophylact
strategi
prevent
tumor
recurr
elimin
residu
tumor
cell
